Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Georges Azzi

Hematology & Oncology Fort Lauderdale, FL Medical Doctor

NPI 1265743017 CMS profile 1401680

4725 N Federal Hwy, Fort Lauderdale, FL 33308

Open in the dashboard

General payments

$117,976

1,123 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,054,022 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Georges Azzi of Fort Lauderdale, FL is reported in the CMS Open Payments database as having received $117,976 across 1,123 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,054,022 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $16,323 231
2024 General $24,246 260
2023 General $46,457 219
2022 General $9,963 153
2021 General $11,747 139
2020 General $630 29
2019 General $8,609 92

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Georges Azzi
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Georges Azzi were reported at $16,323. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Georges Azzi Hematology & Oncology median Middle half National median
2019 $8,609 $529 $121–$2,516 $163
2020 $630 $339 $82–$2,213 $114
2021 $11,747 $263 $49–$1,965 $132
2022 $9,963 $416 $103–$2,395 $149
2023 $46,457 $542 $125–$2,646 $160
2024 $24,246 $692 $141–$3,008 $164
2025 $16,323 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Adaptive Biotechnologies Corporation $49,895 47 payments
  2. Astellas Pharma US Inc $16,420 43 payments
  3. Pfizer Inc. $5,700 127 payments
  4. Gilead Sciences, Inc. $4,707 17 payments
  5. Novartis Pharmaceuticals Corporation $4,683 131 payments
  6. Seattle Genetics, Inc. $4,598 24 payments
  7. Exelixis Inc. $3,827 17 payments
  8. E.R. Squibb & Sons, L.L.C. $3,780 42 payments
  9. Astellas Pharma Global Development $3,697 3 payments
  10. AstraZeneca Pharmaceuticals LP $3,254 66 payments
  11. Other $17,416 606 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $52,589 22 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $29,686 13 payments
  3. Food and Beverage $20,898 1,005 payments
  4. Travel and Lodging $8,658 28 payments
  5. Long term medical supply or device loan $3,181 37 payments
  6. Honoraria $2,313 3 payments
  7. Education $650 15 payments
Products named General payments · program years 2019–2025
  1. clonoSEQ Oncology $39,811 28 payments
  2. PADCEV Oncology $19,702 25 payments
  3. clonoSEQ B-Cell Acute Lymphoblastic Leukemia $8,591 15 payments
  4. PADCEV Oncology $4,322 8 payments
  5. CABOMETYX $3,749 13 payments
  6. KISQALI $3,476 75 payments
  7. OPDIVO $3,188 24 payments
  8. INLYTA $2,238 31 payments
  9. BAVENCIO $2,190 19 payments
  10. Yescarta $1,690 1 payment
  11. Other $24,314 1,222 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 48 drugs

Part D claims

1,328

Median for Hematology-Oncology: 604

Drug cost

$3,393,198

Median for Hematology-Oncology: $1,306,514

Branded share of claims

40.5%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lenalidomide Generic 55 $673,552
Cabometyx Cabozantinib S-Malate Brand 20 $519,464
Erleada Apalutamide Brand 24 $346,465
Inlyta Axitinib Brand 14 $293,388
Revlimid Lenalidomide Brand 26 $255,505
Alunbrig Brigatinib Brand 12 $241,076
Sprycel Dasatinib Brand 13 $233,403
Xtandi Enzalutamide Brand 19 $224,665
Venclexta Venetoclax Brand 14 $214,465
Zarxio Filgrastim-Sndz Brand 28 $103,317

The 10 drugs with the highest cost, of 48 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$111,597

Medicare's payments for the services billed

Medicare patients

376

Average age 76

Services billed

1,287

140 women, 236 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Cancer 48%
Ischemic heart disease 47%
Chronic kidney disease 38%
Diabetes 34%
Depression 32%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 88 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Padcev
$6,346 — —
KISQALI
$1,124 — —
KEYTRUDA
$275 — —
VENCLEXTA
$145 14 —
Lenvima
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 88 with Patron

Records

1,123 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record